Article Text

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
  1. M. Yates1,2,
  2. R. Watts1,
  3. I. Bajema3,
  4. M. Cid4,
  5. B. Crestani5,
  6. T. Hauser6,
  7. B. Hellmich7,
  8. J. Holle8,
  9. M. Laudien9,
  10. M. Little10,
  11. R. Luqmani11,
  12. A. Mahr12,
  13. P. Merkel13,
  14. J. Mills14,
  15. J. Mooney15,
  16. M. Segelmark16,
  17. V. Tesar17,
  18. K. Westman18,
  19. A. Vaglio19,
  20. N. Yalçındağ20,
  21. D. Jayne21,
  22. C. Mukhtyar2
  1. 1Norwich Medical School, University of East Anglia
  2. 2Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
  3. 3Pathology, Leiden University Medical Center, Leiden, Netherlands
  4. 4Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  5. 5Department of Pulmonology, Bichat-Claude Bernard University Hospital, Paris, France
  6. 6Immunologie-Zentrum Zürich, Zürich, Switzerland
  7. 7Klinik für Innere Medizin, Kirchheim-Teck
  8. 8Rheumazentrum Schleswig-Holstein Mitte, Neumünster
  9. 9Department of Otorhinolaryngology, University of Kiel, Kiel, Germany
  10. 10Trinity Health Kidney Centre, Dublin, Ireland
  11. 11Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
  12. 12Hôpital Saint-Louis, Paris, France
  13. 13University of Pennsylvania, Philadelphia, United States
  14. 14Vasculitis UK, Matlock
  15. 15University of East Anglia, Norwich, United Kingdom
  16. 16Linköping University, Linköping, Sweden
  17. 17Charles University, Prague, Czech Republic
  18. 18Skåne University Hospital, Lund and Malmö, Sweden
  19. 19University Hospital of Parma, Parma, Italy
  20. 20Ankara University, Ankara, Turkey
  21. 21Addenbrooke's Hospital, Cambridge, United Kingdom


Background The European League Against Rheumatism (EULAR) Recommendation for primary and small vessel vasculitis were published in 2009.

Objectives To update the 2009 recommendations with the focus being ANCA-Associated Vasculitis (AAV) using systematic literature review, as well as expert opinion where appropriate.

Methods A combined taskforce from European League Against Rheumatism (EULAR), the European Renal Association (ERA-EDTA) and European Vasculitis Society (EUVAS) conducted a modified Delphi exercise to identify key areas of guideline for update. The identified themes were then used to generate keywords for literature searches. For the purpose of update a date period of 1st January 2007 to 1st February 2015 was chosen, to interrogate the main medical literature databases (MEDLINE, EMBASE, CENTRAL). From an initial 1,347 hits, 82 clinically relevant studies were identified. The evidence presented was discussed and summarized by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined.

Results The 15 recommendations cover general aspects, such as attainment of remission and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting immunosuppressive therapy using a strategy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance. For remission induction of life or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy. Azathioprine, rituximab and methotrexate are the preferred choices for remission maintenance. The recommendations address plasma exchange which is recommended, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. To enable the recommendations to have maximum validity the voting process was also repeated amongst the members of EUVAS.

Conclusions The recommendations have been updated and changes include; choice of drug therapy (both for induction, relapse and remission maintenance), monitoring for complications, the usefulness of repeated biopsy in those thought to having relapsing disease, monitoring for hypoimmunoglobulinaemia and recommendations on patient education. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.